These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 18625421)

  • 1. Drug therapy in amyotrophic lateral sclerosis.
    Distad BJ; Meekins GD; Liou LL; Weiss MD; Carter GT; Miller RG
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):633-51, xi-xii. PubMed ID: 18625421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial cells in ALS: the missing link?
    Raibon E; Todd LM; Möller T
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):441-59, vii-viii. PubMed ID: 18625409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)].
    Yanagisawa N; Shindo M
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1329-30. PubMed ID: 9128396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
    Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
    Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Etiological drug therapy for amyotrophic lateral sclerosis].
    Cintas P
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S220-4S227. PubMed ID: 17128115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cotreatment of amyotrophic lateral sclerosis patients].
    Iwasaki Y; Ikeda K
    Rinsho Shinkeigaku; 1999 Dec; 39(12):1253-5. PubMed ID: 10791091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALSUntangled No. 8: Low dose naltrexone for ALS.
    ALSUntangled Group
    Amyotroph Lateral Scler; 2011 Jan; 12(1):76-8. PubMed ID: 21174518
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyperimmune goat serum for amyotrophic lateral sclerosis.
    Mackenzie R; Kiernan M; McKenzie D; Youl BD
    J Clin Neurosci; 2006 Dec; 13(10):1033-6. PubMed ID: 16996272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
    Dib M
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy, lithium, and amyotrophic lateral sclerosis.
    Pasquali L; Longone P; Isidoro C; Ruggieri S; Paparelli A; Fornai F
    Muscle Nerve; 2009 Aug; 40(2):173-94. PubMed ID: 19609902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does treating schizophrenia reduce the chances of developing amyotrophic lateral sclerosis?
    Stommel EW; Graber D; Montanye J; Cohen JA; Harris BT
    Med Hypotheses; 2007; 69(5):1021-8. PubMed ID: 17475413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical development of levetiracetam for amyotrophic lateral sclerosis.
    Davies SL; Moral MA
    Drug News Perspect; 2006 Nov; 19(9):572-3. PubMed ID: 17220961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective agents for clinical trials in ALS: a systematic assessment.
    Traynor BJ; Bruijn L; Conwit R; Beal F; O'Neill G; Fagan SC; Cudkowicz ME
    Neurology; 2006 Jul; 67(1):20-7. PubMed ID: 16832072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy development for ALS: lessons learned and path forward.
    Lanka V; Cudkowicz M
    Amyotroph Lateral Scler; 2008 Jun; 9(3):131-40. PubMed ID: 18574756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine].
    Gámez J
    Neurologia; 2008 Oct; 23(8):484-93. PubMed ID: 18802797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series study.
    Galbussera A; Tremolizzo L; Brighina L; Testa D; Lovati R; Ferrarese C; Cavaletti G; Filippini G
    Neurol Sci; 2006 Jul; 27(3):190-3. PubMed ID: 16897634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of exercise in amyotrophic lateral sclerosis.
    Chen A; Montes J; Mitsumoto H
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):545-57, ix-x. PubMed ID: 18625415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axon guidance proteins: novel therapeutic targets for ALS?
    Schmidt ER; Pasterkamp RJ; van den Berg LH
    Prog Neurobiol; 2009 Aug; 88(4):286-301. PubMed ID: 19523502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.